69222-61-3

Basic information

• Product Name: 2H-Cyclopenta[b]furan-2-one, hexahydro-4-(hydroxymethyl)-5-[(tetrahydro-2H-pyran-2-yl)oxy]-, (3aR,4S,5R,6aS)-
• Synonyms: 2H-Cyclopenta[b]furan-2-one, hexahydro-4-(hydroxymethyl)-5-[(tetrahydro-2H-pyran-2-yl)oxy]-, (3aR,4S,5R,6aS)-;Corey lactone THP;(3aR,4S,5R,6aS)-Hexahydro-4-(hydroxymethyl)-5-[(tetrahydro-2H-pyran-2-yl)oxy]-2H-cyclopenta[b]furan-2-one;Corey lactone;2H-Cyclopenta[b]furan-2-one, hexahydro-4-(hydroxymethyl)-5-[(tetrahydro-2H-pyran-2-yl)oxy]-, (3aR,4S,5R,6aS)- (9CI);(3aR,4S,5R,6aS)-4-(hydroxymethyl)-5-(tetrahydro-2H-pyran-2-yloxy)hexahydro-2H-cyclopenta[b]furan-2-one;2H-Cyclopenta[b]furan-2-one;hexahydro-4-(hydroxyMethyl)-5-[(tetrahydro-2H-pyran-2-yl)oxy]-
• CAS NO: 69222-61-3
• Molecular Formula: C₁₃H₂₀O₅
• Molecular Weight: 256.29
• Product Categories: API intermediates
• Mol File: 69222-61-3.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 454.2±45.0 °C(Predicted)
• Appearance: Colorless or light yellow viscous liquid
• Density: 1.26
• Refractive Index: 1.531
• Storage Temp.: 2-8°C
• PKA: 14.79±0.10(Predicted)
• CAS DataBase Reference: 2H-Cyclopenta[b]furan-2-one, hexahydro-4-(hydroxymethyl)-5-[(tetrahydro-2H-pyran-2-yl)oxy]-, (3aR,4S,5R,6aS)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-Cyclopenta[b]furan-2-one, hexahydro-4-(hydroxymethyl)-5-[(tetrahydro-2H-pyran-2-yl)oxy]-, (3aR,4S,5R,6aS)-(69222-61-3)
• EPA Substance Registry System: 2H-Cyclopenta[b]furan-2-one, hexahydro-4-(hydroxymethyl)-5-[(tetrahydro-2H-pyran-2-yl)oxy]-, (3aR,4S,5R,6aS)-(69222-61-3)

Safety Data

• Hazardous Substances Data: 69222-61-3(Hazardous Substances Data)

Usage

Description

2H-Cyclopenta[b]furan-2-one, hexahydro-4-(hydroxymethyl)-5-[(tetrahydro-2H-pyran-2-yl)oxy]-, (3aR,4S,5R,6aS)is a complex organic compound belonging to the class of furan heterocyclic derivatives. Its unique molecular structure, characterized by a cyclopenta[b]furan-2-one core with hexahydro, hydroxymethyl, and tetrahydro-2H-pyran-2-yloxy substituents, endows it with potential applications in various fields, particularly in pharmaceutical research and development.

Uses

Used in Pharmaceutical Industry:
2H-Cyclopenta[b]furan-2-one, hexahydro-4-(hydroxymethyl)-5-[(tetrahydro-2H-pyran-2-yl)oxy]-, (3aR,4S,5R,6aS)is used as a pharmaceutical intermediate for the synthesis of novel drug candidates. Its unique molecular structure and heterocyclic nature make it a promising candidate for the development of new therapeutic agents with potential applications in treating various diseases and medical conditions.
Used in Medical Experimental Research:
In the field of medical experimental research, 2H-Cyclopenta[b]furan-2-one, hexahydro-4-(hydroxymethyl)-5-[(tetrahydro-2H-pyran-2-yl)oxy]-, (3aR,4S,5R,6aS)serves as a valuable compound for studying the properties and mechanisms of action of furan heterocyclic derivatives. Its synthesis and modification can provide insights into the development of new drugs and therapeutic strategies, contributing to the advancement of medical science and healthcare.

InChI:InChI=1/C13H20O5/c14-7-9-8-5-12(15)17-10(8)6-11(9)18-13-3-1-2-4-16-13/h8-11,13-14H,1-7H2/t8-,9-,10+,11-,13?/m1/s1

Upstream product

• 32233-38-8 3α,5α-dihydroxy-2β-(benzyloxymethyl)cyclopentane-1α-acetic acid γ-lactone 3-tetrahydropyran-2-yl ether 
• 32233-41-3 (3aR,4R,5R,6aS)-hexahydro-2-oxo-5-<(tetrahydro-2H-pyran-2-yl)oxy>-2H-cyclopentafuran-4-carboxaldehyde 
• 110-87-2 3,4-dihydro-2H-pyran 
• 57026-61-6 5-oxo-1-cyclopenten-1-acetic acid methyl ester 
• 88147-21-1 2-methoxycarbonylmethyl-4-hydroxy-2-cyclopenten-1-one 
• 114716-07-3 (R)-2-methoxycarbonylmethyl-4-hydroxy-2-cyclopenten-1-one 
• 947752-04-7 [(R)-5-Oxo-3-(tetrahydro-pyran-2-yloxy)-cyclopent-1-enyl]-acetic acid methyl ester 
• 53813-10-8 (3aR,4S,5R,6aS)-4-Nitromethyl-5-(tetrahydro-pyran-2-yloxy)-hexahydro-cyclopenta[b]furan-2-one 
• 114647-67-5 (3R,1'R)-5-(1'-carboxy-3'-methylbutoxy)imino-3-hydroxy-1-cyclopentene-1-acetic acid methyl ester 
• 114647-58-4 [(1R,2S,3R)-2-Nitromethyl-5-oxo-3-(tetrahydro-pyran-2-yloxy)-cyclopentyl]-acetic acid methyl ester 
• 31767-37-0 6-Benzyloxymethyl-7-hydroxy-8-iodo-2-oxabicyclo<3.3.0>octan-3-one 
• 62447-84-1 (3aR,4S,5S,6R,6aR)-4-Benzyloxymethyl-6-iodo-5-(tetrahydro-pyran-2-yloxy)-hexahydro-cyclopenta[b]furan-2-one 
• 65025-95-8 (3aR,4S,5R,6aS)-4-({[dimethyl(2-methyl-2-propanyl)silyl]oxy}methyl)-5-(tetrahydro-2H-pyran-2-yloxy)hexahydro-2H-cyclopenta[b]furan-2-one 
• 32233-40-2 (3aR,4S,5R,6aS)-5-hydroxy-4-(hydroxymethyl)hexahydro-2H-cyclopenta[b]furan-2-one 

Downstream Products

• 32233-40-2 (3aR,4S,5R,6aS)-5-hydroxy-4-(hydroxymethyl)hexahydro-2H-cyclopenta[b]furan-2-one 
• 65025-95-8 (3aR,4S,5R,6aS)-4-({[dimethyl(2-methyl-2-propanyl)silyl]oxy}methyl)-5-(tetrahydro-2H-pyran-2-yloxy)hexahydro-2H-cyclopenta[b]furan-2-one 
• 773825-80-2 7,7-difluoro-16S,20-dimethyl-18,19-didehydro prostaglandin I₂ 
• 256382-23-7 5-thia-16-(3-methoxymethylphenyl)methylPGE₁ 
• 256382-08-8 Rivenprost 
• 256382-45-3 16-(3-methoxymethyl)phenyl-ω-tetranor-5-thiaprostaglandin F₁ methyl ester 11,15-bis(tetrahydropyran-2-yl ether) 
• 256382-40-8 6-{(1E)-4-[3-(methoxymethyl)phenyl]-3-oxobut-1-enyl}-7-(2H-3,4,5,6-tetrahydropyran-2-yloxy)(5S,7S,1R,6R)-2-oxabicyclo[3.3.0]octan-3-one 
• 256382-41-9 6-{(1E)(3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl}-7-(2H-3,4,5,6-tetrahydropyran-2-yloxy)(5S,7S,1R,6R)-2-oxabicyclo[3.3.0]octan-3-one 
• 256382-42-0 6-{(1E)(3S)-3-(2H-3,4,5,6-tetrahydropyran-2-yloxy)-4-[3-(methoxymethyl)phenyl]but-1-enyl}-7-(2H-3,4,5,6-tetrahydropyran-2-yloxy)(5S,7S,1R,6R)-2-oxabicyclo[3.3.0]octan-3-one 
• 457955-36-1 11(R),15(S)-bis(tetrahydro-2-pyranyloxy)-5,9(S)-dihydroxy-16-(3-methoxymethyl)phenyl-1,2,3,4,17,18,19,20-octanorprostanoic acid 
• 256382-46-4 16-(3-methoxymethyl)phenyl-ω-tetranor-5-thiaprostaglandin E₁ methyl ester 11,15-bis(tetrahydropyran-2-yl ether) 
• 443796-72-3 Toluene-4-sulfonic acid (E)-6-[(1R,2S,3R,5R)-2-(tert-butyl-dimethyl-silanyloxymethyl)-5-chloro-3-(tetrahydro-pyran-2-yloxy)-cyclopentyl]-hex-4-enyl ester 
• 1262872-82-1 isopropyl 4-[(3S,5aR,6R,7R,8aS)-7-hydroxy-6-[(E,3R)-3-hydroxy-4-phenoxy-but-1-enyl]-3,4,5,5a,6,7,8,8a-octahydro-2H-cyclopenta[b]oxepin-3-yl]butanoate 
• 1262872-80-9 2-propanyl 4-[(3S,5aR,6R,7R,8aS)-6-[(1E)-3-oxo-4-phenoxy-1-buten-1-yl]-7-(tetrahydro-2H-pyran-2-yloxy)octahydro-2H-cyclopenta[b]oxepin-3-yl]butanoate 

Relevant articles and documents

The preparation method of the ruby's forefront

The invention relates to a preparation method of lubiprostone, and concretely relates to a preparation method of highly pure lubiprostone represented by formula (I). The method comprises the steps of reducing an initial compound, oxidizing, and hydrolyzing in order to obtain a target compound. Compared with other methods, the method provided by the invention has the advantages of good process reappearance, simple operation, high yield, low cost, high purity of the above obtained product, suitableness for industrialized production, and very high economic benefit.

METHOD FOR TREATING SCHIZOPHRENIA

The present invention provides a novel fatty acid derivative. The present invention also provides use of an effective amount of a fatty acid derivative for treating schizophrenia in a mammalian subject.

STEREOSPECIFIC NITROMETHANE CONJUGATE ADDITION TO 4-OXYGENATED-2-SUBSTITUTED-CYCLOPENT-2-ENONES: A SIMPLE APPROACH TO PROSTAGLANDINS

The compatibility of nitromethane conjugate addition to 2-cyclopentenones bearing a 4-oxygenated function has been illustrated through a short and practical synthesis of the Corey aldehyde, a key intermediate in prostaglandin synthesis, in both racemic and optically active form.A new synthesis of PGF2α featuring the introduction of the ω-chain via cycloaddition has been also described.